Z. Einbeigi1, D. Bergström2, T. Hatschek3 and M. Malmberg4 1Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden. 2Roche AB, Stockholm, Sweden. 3Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden. 4Department of Oncology, Helsingborg Hospital, Helsingborg, Sweden. Abstract Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m2, paclitaxel 155 mg/m2 (both day 1) and capecitabine 665 mg/m2 twice daily (days 1–14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively.